Truong, Van Thi Thanh
Green, Charles
Pedroza, Claudia
Hwang, Lu-Yu
Rajan, Suja S.
Suchting, Robert
Cinciripini, Paul
Tyndale, Rachel F.
Lerman, Caryn
Article History
Received: 8 May 2022
Accepted: 25 April 2023
First Online: 29 April 2023
Declarations
:
: The Committee for the Protection of Human Subjects at the University of Health Science Center at Houston, Texas, USA determined that this study was qualified for exempt status and granted a waiver of informed consent. All methods were carried out in accordance with relevant guideline and regulations.
: Not applicable.
: RFT has consulted for Quinn Emanuel and Ethismos Research Inc. The Pharmacogenetics of Nicotine Addiction Treatment clinical trial received study medication and placebo, and packaging from Pfizer. The remaining authors declare no conflicts of interest.